The Role of Ascorbic Acid on Endothelial Cell Damage in Phacoemulsification
ABSTRACT: The objective of
this study is to compare the corneal endothelial cell loss due to
phacoemulsification surgery in ascorbic acid group and placebo group. This was
a clinical study with double blinds randomized controlled trial. There were 66
subjects enrolled, divided into 2 groups: ascorbic acid group that was given 2
g orally with divided doses 500 mg four times at night, morning, afternoon and
2 hours before surgery (n = 32) and placebo group (n = 34). Endothelial cell
counts was performed before and 7 days after phacoemulsification surgery.
Administration of 2g ascorbic acid in divided doses of 500 mg given 4 times
before phacoemulsification surgery caused less corneal endothelial cell loss
229,27 ± 191,58 cells/mm2 (9.10% ± 6.88%) compared with the administration of placebo
which had endothelial cell loss 364,64 ± 255,25 cells/mm2 (14.85% ± 10.54%).
There was statistically significantly different in endothelial cell loss
between the two groups (p < 0.05), but no clinically significantly
different. The baseline characteristic between the both groups was similar.
Administration of 2 g ascorbic acid in divided doses of 500 mg given 4 times
before phacoemulsification surgery can reduce the corneal endothelial cell
loss.
Penulis: Nika Bellarinatasari,
Wasisdi Gunawan, Tri Wahyu Widayanti, Hartono
Kode Jurnal: jpkedokterandd110019
